Symphony Financial Services Inc. Has $360,000 Stake in Pfizer Inc. (NYSE:PFE)

Symphony Financial Services Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 15.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,563 shares of the biopharmaceutical company’s stock after acquiring an additional 1,765 shares during the period. Symphony Financial Services Inc.’s holdings in Pfizer were worth $360,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of PFE. Snider Financial Group bought a new position in Pfizer in the 4th quarter worth $362,000. Glass Wealth Management Co LLC increased its position in Pfizer by 0.7% during the fourth quarter. Glass Wealth Management Co LLC now owns 104,395 shares of the biopharmaceutical company’s stock worth $2,770,000 after acquiring an additional 709 shares during the period. Victory Capital Management Inc. grew its position in Pfizer by 47.8% in the 4th quarter. Victory Capital Management Inc. now owns 5,152,861 shares of the biopharmaceutical company’s stock worth $136,705,000 after purchasing an additional 1,666,189 shares during the last quarter. Ariston Services Group bought a new stake in shares of Pfizer in the fourth quarter valued at about $269,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of analyst reports. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Finally, Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Trading Down 2.0 %

PFE opened at $25.72 on Wednesday. The firm’s fifty day simple moving average is $26.32 and its 200 day simple moving average is $27.28. The stock has a market capitalization of $145.73 billion, a P/E ratio of 18.24, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. Pfizer’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.69%. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.